{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"}],"units":"Participants"}],"description":"Number of participants who discontinued the protocol due to adverse events.","groups":[{"description":"Subjects will be started on recombinant interferon-α at a dose of 3 million units SQ daily, escalating the dose by 1 million units every week as tolerated to a maximum dose of 3 million units/m2/day. Following a minimum of one month of interferon therapy with two weeks on a stable dose, subjects will begin recombinant interleukin-6 therapy at a dose of 2.5 ug/kg/day.\n\nrecombinant interferon-α\n\nrecombinant interleukin-6","id":"OG000","title":"Interleukin-6 and Interferon-α"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Up to 5 months","title":"Toxicity as Measured by Number of Participants Who Discontinued Treatment Due to Adverse Events","type":"PRIMARY","unitOfMeasure":"Participants"}